


Modified slides

Pharmacology



Lecture #6



Writer: Aya Eyad



[Ju dentistry.com](http://Ju.dentistry.com)




هَمَّةُ الأَسْنَانِ

Pharmacodynamics

Drug Receptor Interactions

Drug → Receptor → Effects




The drug will bind to same binding site of endogenous ligand and make a positive response

Competitive inhibitor

Bind to another site, not the binding site

Competitive agonist will bind reversibly to the binding site

Competitive antagonist will bind reversibly to the binding site



Drug Receptor Interactions

- **Agonists** bind to the agonist binding site and produce an action.
- **Competitive inhibitors** bind to the same site, to prevent the binding of the agonist, and produce no action.
- **Allosteric activators** act at separate sites to increase the efficacy of the agonist or its binding affinity.
- **Allosteric Inhibitors** act at separate sites to decrease the efficacy of the agonist or its binding affinity

Possibilities of Drug Combinations

- **Antagonistic Effects**
- **Additive Effects.**
- **Synergistic Effects.**
- **No effect.**

And potentiation effect

Drug Antagonism

- **Pharmacologic Antagonism:**
 - Competitive Antagonism
 - Noncompetitive antagonism

Epinephrin will not compete to histamine receptors, but it will bind to other receptors and antagonize the physiological effect of histamine

- **Physiologic Antagonism:**

- **Epinephrine in Anaphylaxis**

Reverses all of these allergic symptoms

Severe allergic reaction :
Decrease blood pressure,
bronchoconstriction, increased
Histamine release and swelling of
some organs

- **Chemical Antagonism:**
 - Antacids in heartburn.

Pharmacologic Antagonism

- **Competitive Antagonism:** *The drug has to bind reversibly*
 - Antagonist binds to the same site of agonist binding and prevents its binding and consequently its effects.
- **Noncompetitive antagonism:** *Or irreversible*
 - Antagonist binds to a site on the receptor separate from the agonist binding site and prevents receptor activation without blocking agonist binding.

Agonist-Antagonist Relationships

- **Competitive antagonist**, higher concentrations of agonist are required to produce a given effect. High agonist concentrations can overcome inhibition by a competitive antagonist.
- **Irreversible (or noncompetitive) antagonist**, reduces the maximal effect the agonist can achieve, although it may not change its EC50.

Possibilities of Drug Combinations

- **Antagonistic Effects**

- **Additive Effects**

Additive drug effect occurs if two drugs with the same effect, when given together produce an effect that is equal in magnitude to the sum of the effect.

$$E_{AB} = E_A + E_B$$

$$1 + 1 = 2$$

- **Synergistic Effects:**

Interaction between two or more **drugs** or agents resulting in a pharmacologic response greater than the sum of individual responses to each **drug** or agent

$$E_{AB} > E_A + E_B$$

$$1 + 1 > 2$$

So they both have the same effect
Sulfamethoxazole + trimethoprim = cotrimexazole
Folic acid antagonist Inhibits dihydrofolate reductase

- **Potentiation Effects:**

Potentiation drug effect occurs if a drug lacking an effect of its own increase the effect of a second active drug.



$$E_{AB} > \overset{= \text{zero}}{E_A} + E_B$$

$$0 + 1 > 1$$

Receptors are an Excellent Drug Target

- Activated receptors directly, or indirectly, regulate cellular biochemical processes within and between cells to change cell function.
- Recognition sites are precise molecular regions of receptor macromolecules to which the ligand binds providing:
Because of the 3D structure of receptors
- Specificity: Only a subset of receptors will be targets
- Selectivity: Since receptors are coupled to specific signaling pathways
- Sensitivity: Receptor binding events are amplified intracellularly

Specificity: Lock and key



The precise fit required of the ligand”**KEY**


The activation of the receptors.....The opening of the “**LOCK**”

This interaction shows high degree of **specificity**

Selectivity

Different tissues= different signaling pathway= different responses

Notice that same ligand made different responses



(a) Signaling pathway	(b) Number of molecules activated
RECEPTION Binding of epinephrine to G protein-linked receptor ↓	1 molecule
TRANSDUCTION Inactive G protein → Active G protein	10^2 molecules
Inactive adenylyl cyclase → Active adenylyl cyclase	10^2 molecules
ATP → Cyclic AMP	10^4 molecules
Inactive protein kinase A → Active protein kinase A	10^4 molecules
Inactive phosphorylase kinase → Active phosphorylase kinase	10^5 molecules
Inactive glycogen phosphorylase → Active glycogen phosphorylase	10^6 molecules
RESPONSE Glycogen → Glucose-1-phosphate	10^8 molecules

Signal Amplification

- Receptor binding are amplification terms of duration and intensity
- Example: G-protein coupled receptors
- Phenomena that account for the amplification:
 1. The receptor drug-complex can interact with many G proteins thereby multiplying the organ signal many folds.
 2. The activated G-protein persists for longer duration than the original receptor-drug complex **More time more amplification**

Orphan Receptors

We dont know the ligand,and we dont know the function

- **Receptors which no ligand has been discovered and whose function can only be hypothesized.**

Drug Receptors & Pharmacodynamics

Receptor interactions determine the quantitative relations between concentration of drug and pharmacologic effects.

- The receptor's affinity for binding a drug determines the concentration of the drug required to form a significant number of drug-receptor complexes,
- The total number of receptors is usually much smaller than the number of drug molecules.
- This will limit the maximal effect a drug may produce.


Dose response relationships

- Graded dose-response relations

As the dose administered to single subject or isolated tissue is increased, the pharmacologic effect will also increase.

At a certain dose, the effect will reach a maximum level, which is called the ceiling effect or E_{max} .

Relations between drug concentration and drug effect



A

Receptor Occupancy Theory

The “Law” of Mass Action

- **Activation of membrane receptors and target cell responses is *proportional to the degree of receptor occupancy*.**
- **Assumptions:**
 - Association is limited by collision, orientation and energy
 - All receptors are equally accessible
 - All receptors are either free or bound, there is no “partial” binding
 - Neither drug or receptor are altered by binding
 - Binding is reversible

As doses increase.....the response increment diminishes

Vmax قبل ما أوصول

كل ما أزيد تركيز الدواء بزيد أثره، ولكن معدل الزيادة بقل=

The curve is flattening more toward the end and may reach plateau

The relation between drug concentration and effect is described by a hyperbolic curve

$$E = \frac{E_{\max} \times C}{C + EC_{50}}$$

E = the effect observed at concentration C

E max =the maximal response that can be produced by the drug

EC 50 = the concentration of drug that produces 50% of maximal effect.

mass action law:

which describes association between two molecules of a given **affinity**.

This resemblance suggests that drug agonists act by binding to (“occupying”) a distinct class of biologic molecules with a characteristic affinity for the drug receptor.


$$B = \frac{B_{\max} \times C}{C + K_d}$$

In these systems, drug bound to receptors (B) relates to the concentration of free (unbound) drug (C)

B_{\max} = the total concentration of receptor sites

K_d = the equilibrium dissociation constant.

Relations between drug concentration and receptor-bound drug



B

Source: Katzung BG, Masters SB, Trevor AJ: *Basic & Clinical Pharmacology*, 11th Edition: <http://www.accessmedicine.com>

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

K_d (the equilibrium dissociation constant)

represents the concentration of free drug at which half-maximal binding is observed.

This constant characterizes the receptor's affinity for binding the drug in a reciprocal fashion:

If the K_d is low, binding affinity is high

If K_d is High , binding affinity is low versa.

The EC 50 and K_d may be identical,

But not necessarily .


Potency =affinity

Represented by EC50

- Potency refers to the affinity of a drug for its receptor or the concentration of drug required to produce a given effect. Low KD, high potency
- • Potency refers to the amount or concentration of drug required to produce a response.
- • On dose-response curves potency is measured on the X-axis.
- • ED50, EC50, and Kd are measures of potency.


The dose of drug that gives me 50% of the max effect

Graduate dose-response curve



Drug A is more potent, because we need to use less dose of it to reach $1/2$ the E_{max}

efficacy =E_{max}

- Efficacy is the maximum effect of a drug, E_{max}, and does depend on the number of drug-receptor complexes formed, and also on the efficiency of the of coupling of receptor activation to cellular responses. *Intrinsic activity*

- Aspirin and morphine produce the same pharmacologic effect (analgesia) but have very different levels of efficacy. *مسكنات*
Morphine has higher efficacy so it has higher effect

efficacy

- If drug can stimulate a receptor to produce a biological response it is said to have efficacy.
- Efficacy refers to the capacity of a drug to produce an effect or the overall magnitude of the maximum response, synonymous with **intrinsic activity**
- If a drug stimulates a full response, it might to said to be a full agonist and to be very efficacious.

Receptor-effector Coupling

When a receptor is occupied by an agonist
— — — — A conformational change occurs.

The transduction process that links drug occupancy of receptors and pharmacologic response is often termed **coupling**.

The ability of drug to bind to receptor and cause conformational change and pharmacologic response

Receptor-effector Coupling


The relative efficiency of occupancy-response coupling is partially determined by the initial conformational change in the receptor.

Coupling efficiency is also determined by the biochemical events that transduce receptor occupancy into cellular response.

Can produce max effect

Full agonists can be considered more efficiently coupled to receptor occupancy than can the effects of partial agonists

Log dose response curve



- The smaller the EC₅₀, the greater the potency.
- Efficacy is indicated by the height of the log dose response

الاحتياط



Spare receptors

Only a fraction of total receptors for a specific ligand may need to be occupied to elicit a maximum response.

Examples:


- To reach max response we need to occupy only 1% of the receptors!!
Insulin receptors are estimated to have 99% of the receptors as spare receptors..... large functional reserve to ensure adequate control of glucose uptake.
- Only 5-10% of beta adrenoceptors are spare.....little functional reserve exist in the failing heart. So most receptors need to be occupied for a maximum effect

Emax will not be changed




A

Competitive Inhibition



B

Noncompetitive Inhibition



QUANTAL DOSE–RESPONSE RELATIONSHIPS

- A Dose–response relationship is that between the dose of the drug and the proportion of a population that responds to it.
- **All or none.** يا إما بأثر تماما
أو ما بأثر أبداً
- Used to calculate the therapeutic index of drugs

Therapeutic index and margin of safety

Therapeutic index of a drug is a ratio of the dose that produces toxicity to the dose that produces a clinically desired or effective response in a population individuals:

$$TI = \frac{TD_{50}}{ED_{50}} \frac{\text{Toxic}}{\text{Effective}}$$

Where TD_{50} is the minimum dose that is lethal or toxic for 50% of the population, and ED_{50} is the minimum dose that is effective for 50% of the population.

Ideally the TD_{50} Should be a much higher dose than the ED_{50} so that the therapeutic index would be large. =more safe drug

Quantal Dose-Effect Curves

- **Effective Dose (ED50):** is the dose at which 50% of individuals exhibit the specified quantal effect.
- **Toxic Dose (TD50):** is the dose required to produce a particular toxic effect in 50% of animals.
- **Lethal Dose (LD50):** is the dose required to produce death in 50% of the of the animals.

T

Therapeutic index and margin of safety

